Scarica l'app Stockscreener
0.4583
7.66%
0.0327
Precedente Chiudi:
$0.4256
Aprire:
$0.43
Volume 24 ore:
286.28K
Relative Volume:
0.14
Capitalizzazione di mercato:
$64.86M
Reddito:
-
Utile/perdita netta:
$-119.76M
Rapporto P/E:
-0.3395
EPS:
-1.35
Flusso di cassa netto:
$-55.17M
1 W Prestazione:
-2.51%
1M Prestazione:
+10.70%
6M Prestazione:
-20.49%
1 anno Prestazione:
-92.62%
Intervallo 1D:
$0.43
$0.4587
Intervallo di 1 settimana:
$0.422
$0.4833
Portata 52W:
$0.295
$10.62
Applied Therapeutics Inc Stock (APLT) Company Profile
Nome
Applied Therapeutics Inc
Settore
Industria
Telefono
212-220-9226
Indirizzo
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Confronta APLT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
0.4581 | 62.92M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
378.35 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.78 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.14 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
642.76 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.36 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-02 | Downgrade | UBS | Buy → Neutral |
| 2024-11-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-31 | Iniziato | William Blair | Outperform |
| 2024-03-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-02-22 | Iniziato | Leerink Partners | Outperform |
| 2022-01-04 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-08-27 | Downgrade | Goldman | Neutral → Sell |
| 2021-06-25 | Ripresa | Goldman | Neutral |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-04-22 | Iniziato | Goldman | Buy |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2019-06-10 | Iniziato | Citigroup | Buy |
| 2019-06-10 | Iniziato | Cowen | Outperform |
| 2019-06-10 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Applied Therapeutics Inc Borsa (APLT) Ultime notizie
Applied Therapeutics Inc.’s Beta Climbs After Market VolatilityBuy Alerts With Low Risk Confirmation Noted - metal.it
Applied Therapeutics (APLT) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
What institutional investors are buying Applied Therapeutics Inc. stockUnlock powerful investment tools for free - Jammu Links News
What are the latest earnings results for Applied Therapeutics Inc.Free Stock Selection - Jammu Links News
What are analysts’ price targets for Applied Therapeutics Inc. in the next 12 monthsOutstanding growth strategies - Jammu Links News
What catalysts could drive Applied Therapeutics Inc. stock higher in 2025Achieve breakthrough financial results - Jammu Links News
How does Applied Therapeutics Inc. generate profit in a changing economyInvest confidently with professional market insights - Jammu Links News
What are Applied Therapeutics Inc. company’s key revenue driversHigh-octane investment opportunities await - Jammu Links News
How volatile is Applied Therapeutics Inc. stock compared to the marketGet high-impact stock recommendations now - Jammu Links News
Published on: 2025-08-03 15:52:53 - Jammu Links News
Applied Therapeutics Inc. Stock Analysis and ForecastBuild a diversified portfolio for risk management - Jammu Links News
What drives Applied Therapeutics Inc. stock priceMaximize your portfolio’s growth potential - Jammu Links News
What analysts say about Applied Therapeutics Inc. stockBuild a portfolio that delivers consistent profits - Jammu Links News
What makes Applied Therapeutics Inc. stock price move sharplyEarnings Report Entry Points For Fast Growth - Jammu Links News
Applied Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Brokerages Set Applied Therapeutics Inc. (NASDAQ:APLT) PT at $6.10 - MarketBeat
What is the dividend policy of Applied Therapeutics Inc. stockValue Investing Picks For Every Investor - Jammu Links News
Is Applied Therapeutics Inc. still worth holding after the dipBuy Alerts With Low Risk Confirmation Noted - metal.it
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. Lawsuit – APLT - ACCESS Newswire
Wall Street Zen Upgrades Applied Therapeutics (NASDAQ:APLT) to Sell - MarketBeat
Published on: 2025-07-29 13:58:52 - metal.it
Why Applied Therapeutics Inc. stock attracts strong analyst attentionLow Capital High Return Stock Plans Reviewed - metal.it
APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
How does Applied Therapeutics Inc. compare to its industry peersRemarkable growth - jammulinksnews.com
Applied Therapeutics (NASDAQ:APLT) Stock Price Down 5%What's Next? - MarketBeat
What is Applied Therapeutics Inc. company’s growth strategyMaximize your portfolio’s growth potential - jammulinksnews.com
Published on: 2025-07-28 02:44:29 - Jammu Links News
Is Applied Therapeutics Inc. a good long term investmentFree Consultation - PrintWeekIndia
Should I buy Applied Therapeutics Inc. stock before earningsFree Investment Risk Control - Jammu Links News
How Applied Therapeutics Inc. stock reacts to Fed policy changesTop Analyst Picks - Newser
Applied Therapeutics Inc Azioni (APLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Applied Therapeutics Inc Azioni (APLT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Funtleyder Leslie D. | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
14,502 |
6,381 |
390,459 |
| Chinoporos Constantine | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
447 |
197 |
271,436 |
| Funtleyder Leslie D. | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
22,950 |
14,000 |
404,961 |
| Perfetti Riccardo | Chief Medical Officer |
Feb 06 '25 |
Sale |
0.61 |
86,078 |
52,508 |
900,775 |
| Chinoporos Constantine | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
28,117 |
17,151 |
271,883 |
| Funtleyder Leslie D. | Chief Financial Officer |
Aug 22 '24 |
Sale |
5.83 |
13,530 |
78,880 |
277,911 |
| Perfetti Riccardo | Chief Medical Officer |
Aug 22 '24 |
Sale |
5.83 |
22,681 |
132,230 |
986,853 |
| Shendelman Shoshana | President and CEO |
Aug 13 '24 |
Sale |
6.18 |
357,423 |
2,208,874 |
4,810,430 |
| Shendelman Shoshana | President and CEO |
Aug 12 '24 |
Sale |
5.98 |
300,000 |
1,794,000 |
5,167,853 |
| Shendelman Shoshana | President and CEO |
Aug 14 '24 |
Sale |
5.93 |
119,591 |
709,175 |
4,690,839 |
1.07%
1.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):